Cosmos Health Inc. (COSM) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Cosmos Health Inc. is a vertically integrated global healthcare group operating in the pharmaceutical, nutraceutical, and healthcare distribution sectors. The company operates through subsidiaries in Greece, the UK, and Cyprus, focusing on proprietary brands (Sky Premium Life, Mediterranation), generic pharmaceuticals, and contract manufacturing. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics (Six Months Ended June 30, 2025)
| Metric | Value |
|---|---|
| Revenue | $28,458,230 |
| Net Loss | $(3,646,165) |
| Gross Profit | $3,213,613 (11.3% Margin) |
| Operating Loss | $(3,478,464) |
| Cash and Equivalents | $655,503 |
| Working Capital | $(604,249) (Negative) |
| Total Debt (Current + Long Term) | ~$15.2M (Lines of Credit, Notes, Convertible Notes) |
| Stockholders' Equity | $26,231,633 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 2.4% year-over-year (YoY) for the six-month period, driven by higher sales in the UAE, Cyprus, and Greece, and expanded contract manufacturing agreements at the Cana subsidiary.
- Profitability Improvement: Net loss decreased 18.2% YoY to $3.65M. Gross profit surged 52.7% YoY due to a favorable shift in revenue mix toward higher-margin nutraceuticals and contract manufacturing.
- Expense Trends: Operating expenses rose 3.9% YoY, primarily due to increased salaries and wages at the Cana subsidiary. Sales and marketing expenses dropped 82.5% as the company scaled back brand promotion.
- Foreign Currency Impact: Significant favorable foreign currency translation adjustments of $2.59M (vs. a loss of $0.78M in the prior year) resulted from the appreciation of the Euro and British Pound against the USD.
- Debt Structure: The company issued new convertible notes totaling approximately $1.6M in Q2 2025, increasing current liabilities.
Guidance, Outlook, and Risks
- Going Concern: Management has disclosed substantial doubt regarding the company's ability to continue as a going concern for the next 12 months due to negative working capital, accumulated deficits, and reliance on external financing. However, a subsequent financing event (see below) is expected to alleviate this.
- Subsequent Financing: On August 5, 2025, the company entered into a Securities Purchase Agreement for up to $300 million in senior secured convertible notes. An initial $8 million closing occurred on August 6, 2025. Proceeds are intended for digital asset acquisition (Ethereum) and working capital.
- Strategic Initiatives: The company is expanding distribution in the UAE (exclusive agreement for Sky Premium Life), growing the wholesale base of Cosmofarm S.A., and strengthening contract manufacturing at Cana S.A.
- Risks: Key risks include supply chain disruptions, regulatory changes in healthcare pricing, and the need for continued capital raises to meet debt obligations. The company also faces pending litigation regarding tax audits and unpaid bills from hospitals.
- Internal Controls: The company identified material weaknesses in internal controls, specifically regarding segregation of duties and IT general controls, with remediation planned for completion by December 31, 2025.
Investor Verification Checklist
- Financing Execution: Verify the full closing of the $300 million convertible note facility and the actual deployment of funds into digital assets versus working capital.
- UAE Distribution: Confirm the realization of revenue from the exclusive Sky Premium Life distribution agreement in the UAE and the volume of purchase orders received.
- Related Party Transactions: Review the significant balances with Doc Pharma S.A. (related party), including prepaid expenses (~$4.3M) and receivables, to assess collectability and fair value.
- Debt Covenants: Monitor compliance with financial covenants on lines of credit and notes payable, given the negative working capital position.
- Internal Control Remediation: Track progress on fixing material weaknesses in financial reporting and IT controls to ensure future reporting reliability.